Premium
DEK oncogene is overexpressed during melanoma progression
Author(s) -
RiveiroFalkenbach Erica,
Ruano Yolanda,
GarcíaMartín Rosa M.,
Lora David,
Cifdaloz Metehan,
Acquadro Francesco,
Ballestín Claudio,
OrtizRomero Pablo L.,
Soengas María S.,
RodríguezPeralto José L.
Publication year - 2017
Publication title -
pigment cell and melanoma research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.618
H-Index - 105
eISSN - 1755-148X
pISSN - 1755-1471
DOI - 10.1111/pcmr.12563
Subject(s) - melanoma , oncogene , tumor progression , cancer research , immunostaining , biology , cell , pathology , cancer , immunohistochemistry , medicine , immunology , cell cycle , genetics
Summary DEK is an oncoprotein involved in a variety of cellular functions, such as DNA repair, replication, and transcriptional control. DEK is preferentially expressed in actively proliferating and malignant cells, including melanoma cell lines in which DEK was previously demonstrated to play a critical role in proliferation and chemoresistance. Still, the impact of this protein in melanoma progression remains unclear. Thus, we performed a comprehensive analysis of DEK expression in different melanocytic tumors. The immunostaining results of 303 tumors demonstrated negligible DEK expression in benign lesions. Conversely, malignant lesions, particularly in metastatic cases, were largely positive for DEK expression, which was partially associated with genomic amplification. Importantly, DEK overexpression was correlated with histological features of aggressiveness in primary tumors and poor prognosis in melanoma patients. In conclusion, our study provides new insight into the involvement of DEK in melanoma progression, as well as proof of concept for its potential application as a marker and therapeutic target of melanoma.